Systemically circulating colitogenic memory CD4+ T cells may be an ideal target for the treatment of inflammatory bowel diseases

Keio Journal of Medicine

Volumn 58, Issue 4, 2009, Pages 203-209

  Kanai, Takanori ^a   Watanabe, Mamoru ^b   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Colitogenic memory CD4+ T cells; FTY720; Inflammatory bowel disease; Leukocytapheresis

Indexed keywords

ALPHA4 INTEGRIN; BACTERIUM ANTIBODY; CHEMOKINE RECEPTOR CCR9; FINGOLIMOD; HERMES ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NATALIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; RAG1 PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELL THERAPY; CLINICAL TRIAL; COLITIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; GRAFT REJECTION; GRANULOCYTE; HUMAN; KNOCKOUT MOUSE; LEUKAPHERESIS; LEUKOCYTE; LEUKOCYTE ACTIVATION; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; RELAPSE; REVIEW; T CELL LEUKEMIA;

CD4-POSITIVE T-LYMPHOCYTES; COLON; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 75149184215     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.58.203     Document Type: Review

References (56)

1. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657
2. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434
3. Strober, W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549
4. Sartor RB: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407
5. Hibi T, Ogata H: Novel pathophysiological concepts of inflammatory bowel disease. J Gastroteol 2006; 41: 10-16
6. Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF: Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg 2001; 18: 51-55
7. Barrie A, Regueiro M: Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1424-1429
8. Watanabe M, Ueno Y, Yajima T, Okamoto S. Hayashi T. Yamazaki M, Iwao Y, Ishii H, Habu S, Uehira M, Nishimoto H, Ishikawa H, Hata J, Hibi T: Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998; 187: 389-402
9. Yamazaki M, Yajima T, Tanabe M, Fukui K, Okada E, Okamoto R, Oshima S, Nakamura T, T. Kanai T, Uehira M, Takeuchi T, Ishikawa H, Hibi T, Watanabe M: Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol 2003; 171: 1556-1563
10. + mucosal T cells in mice. Am J Physiol Gastrointest Liver Physiol 2005; 288: G745-G754
11. Totsuka T, Kanai T, Nemoto Y, Makita S, Watanabe M: L-7 is essential for the development and the persistence of chronic colitis. J Immunol 2007; 178; 4737-4748
12. Tomita T, Kanai T, Nemoto Y, Totsuka T, Okamoto R, Tsuchiya K, Sakamoto N, Watanabe M: Systemic, but not intestinal, IL-7 is essential for the persistence of chronic colitis. J Immunol 2008; 180: 383-390
13. Gupta A, Derbes C, Sellin J: Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an Academic Medical Center. Inflamm Bowel Dis 2005; 11: 898-902
14. Sartor RB, Muehlbauer M: Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 2007; 9: 497-507
15. +regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-352
16. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F: Regulatory T cells and intestinal homeostasis.Immunol Rev 2005; 204: 184-194
17. Elson CO, Cong Y: Understanding immune-microbial homeostasis in intestine. Immunol Res. 2002; 26: 87-94
18. Mowat AM: Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003; 3: 331-341
19. Coombes JL, Powrie F: Dendritic cells in intestinal immune regulation. Nat Rev Immunol. 2008; 8: 435-446
20. Iwasaki A: Mucosal dendritic cells. Annu Rev Immunol 2007; 25: 381-418
21. Hisamatsu T, Ogata H, Hibi T: Innate immunity in inflammatory bowel disease: state of the art. Curr Opin Gastroenterol 2008; 24: 448-454
22. Mueller C, Macpherson AJ: Layers of mutualism with commensal bacteria protect us from intestinal inflammation. Gut 2006; 55: 276-284
23. Mora JR, von Andrian UH: T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006; 27: 235-243
24. Sigmundsdottir H, Butcher EC: Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008; 9: 981-987
25. +T cells. Nature 2005; 434: 1148-1152
26. + effector and memory T cell generation. Nat Immunol 2003; 4: 835-842
27. Surh CD, Sprent J: Homeostasis of naive and memory T cells. Immunity 2008; 29: 848-862
28. +T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5: 1461-1471
29. Totsuka T, Kanai T, Iiyama R, Uraushihara K, Yamazaki M, Okamoto R, Hibi T, Tezuka K, Azuma M, Akiba H, Yagita H, Okumura K, Watanabe M: Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 2003; 124: 410-421
30. - effector memory T cells. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1051-G1058
31. Singh NJ, Schwartz RH: The lymphopenic mouse in immunology: from patron to pariah. Immunity 2006; 25: 851-855
32. Feillet H, Bach JF: Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr Opin Gastroenterol 2004; 20: 560-564
33. King C, Ilic A, Koelsch K, Sarvetnick N: Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265-277
34. Barber DL, Wherry EJ, Masopust D, Zhu B, Alison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687
35. Klenerman P, Hill A: T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6: 873-879
36. Fry TJ, Mackall CL: The many faces of IL-7: From lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174: 6571-6576
37. Bradley LM, Haynes L, Swain SL: IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol 2005; 26: 172-176
38. +T cells convert to regulatory cells and suppress colitis. Eur J Immunol 2008; 38: 1275-1286
39. Watanabe M, Ueno Y, Yajima T, Iwao Y, Tsuchiya M, Ishikawa H, Aiso S, Hibi T, Ishii H: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest 1995; 95: 2945-2953
40. Fujihashi K, Kawabata S, Hiroi T, Yamamoto M, McGhee JR, Nishikawa S, Kiyono H: Interleukin 2 (IL-2) and interleukin 7 (IL-7) reciprocally induce IL-7 and IL-2 receptors on gamma delta T-cell receptor-positive intraepithelial lymphocytes. Proc Natl Acad Sci USA 1996; 93: 3613-3618
41. th ed. London 2004: 399-424
42. +effector-memory T cells continuously recirculate inchronic colitic mice. Inflam Bowel Dis 2008; 14: 1630-1640
43. Kanai T, Hibi T, Watanabe M: The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006; 6: 453-466
44. Bresci G: Granulocytapheresis in the treatment of patients with active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008; 2: 639-43
45. Shirokaze J: Leukocytapheresis using a leukocyte removal filter. Ther Apher 2002; 6: 261-266
46. + monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis 2007; 13: 284-290
47. Chiba K: FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005; 108: 308-319
48. Cyster JG: Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-159
49. Matsuura M, Imayoshi T, Okumoto T: Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rat. Int J Immunopharmacol 2000; 22: 323-331
50. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S: Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 2002; 29: 707-716
51. Schuurman HJ, Menninger K, Audet M, Kunkier A, Maurer C, Vedrine C, Bernhard M, Gaschen L, Brinkmann V, Quesniaux V: Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplatation, given alone or in combination with cyclosporine or RAD. Transplatation 2002; 74: 951-960
52. Kappos L, Antel J, Comi G,Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW: FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140
53. - effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2006; 291: G267-G274
54. +T cells in bone marrow. Eur J Immunol 2008; 38: 3290-3303
55. MacDonald TT, Pender SLF: Lamina propria T cells. Chem Immunol 1998; 71: 103-117
56. Sandborn WJ, Colombel JF, Enns R,Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group: Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. N Engl J Med 2005; 353: 1912-1925